Clinical trials: Filariasis
Wuchereria Bancrofti Infection
Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)
The study will be an open label cohort study with 2 two-treatment groups 2). Both groups will be treated with a single oral administration of Diethylcarbamazine (DEC) 6 mg/kg + Albendazole (ALB) 400 mg + Ivermectin (IVR) 200…
- Trial name
- NCT02845713
- Testing
- Ivermectin, Diethylcarbamazine Albendazole (IDA)
- Where
- Côte d’Ivoire
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Filariasis
Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside
The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in healthy male caucasian subjects.
- Trial name
- NCT03383614
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Lymphatic Filariases, Scabies
Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji
Lymphatic Filariasis (LF), scabies and soil transmitted helminths (STH) are common neglected tropical diseases affecting the people of Fiji.
- Conditions
- Lymphatic Filariases, Scabies, Impetigo, Soil Transmitted Helminths
- Trial name
- FIT (NCT03177993)
- Testing
- 3 drug dose - IDA, 3 drug dose - IDA with second dose of ivermectin, 2 drug dose - DA
- Where
- Fiji
- Volunteers
- 4,773 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Loiasis, Lymphatic Filariasis
Spontaneous Antigenemia in Loiasis
This prospective study will enroll and follow 60 loiasis patients with high worm burden to monitor the spontaneous release of filarial antigen in peripheral blood.
- Trial name
- NCT04258670
- Testing
- No intervention
- Where
- Cameroon
- Volunteers
- 86 people
- Sponsor
- Washington University School of Medicine
Onchocercal Subcutaneous Nodule, Epilepsy
Onchocerciasis-Associated Epilepsy, an Explorative Case-control Study
This is an exploratory case control study with the aim to compare the Onchocerca volvulus virome between persons with onchocerciasis-associated epilepsy (OAE) and persons with onchocerciasis but without epilepsy.
- Conditions
- Onchocercal Subcutaneous Nodule, Epilepsy, Virus
- Trial name
- NCT05868551
- Testing
- nodulectomy
- Where
- South Sudan
- Volunteers
- 40 people
- Sponsor
- Universiteit Antwerpen
Lymphedema, Lymphatic Filariasis
A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
Current lymphedema management protocols are based on the use of simple measures of hygiene (regular washing with soap and water, skin and nail care), use of topical antibiotics or antifungal agents, exercise and footwear.
- Conditions
- Lymphedema, Lymphatic Filariasis, Filariasis
- Trial name
- LeDoxy-Mali (NCT02927496)
- Testing
- Doxycycline
- Where
- Mali
- Volunteers
- 220 people
- Sponsor
- The Task Force for Global Health
Podoconiosis
Genetic and Other Aspects of Podoconiosis
Background: Podoconiosis is a disease of the lymph vessels in the legs and feet. It is caused by long-term barefoot exposure to irritant soils, such as those in volcanic areas.
- Trial name
- NCT01939431
- Where
- Ethiopia
- Volunteers
- 76 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Non-filarial Elephantiasis
An RCT to Evaluate the Effect of a New Skin Care Regimen on SBF in Those With Podoconiosis
An RCT (n=193) in two podoconiosis clinics in Ethiopia to evaluate the effectiveness of a research based skin management regimen compared to the current regimen.
- Trial name
- NCT02839772
- Testing
- Current skin care regimen plus 2% glycerine added to soaking water, Current skin care regimen
- Volunteers
- 193 people
- Sponsor
- University of Hull
Lymphatic Filariases
Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis
This study will assess the impact of 2-drug (DA) or 3-drug (IDA) regimens on lymphatic filariasis infection parameters in communities.
- Trial name
- NCT03352206
- Testing
- 2 drug dose - DA, 3 drug dose - IDA
- Where
- 5 sites in Fiji, Haiti and 3 more
- Volunteers
- 20,092 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Leprosy, Lymphatic Filariases
Integrating Mental Health Into Neglected Tropical Disease Care in Ghana
Background Neglected Tropical Diseases (NTDs) are a group of diseases that are more common among the poorest people in the poorest countries.
- Conditions
- Leprosy, Lymphatic Filariases, Buruli Ulcer, Onchocerciasis
- Trial name
- IMAGINE (NCT07248462)
- Testing
- WHO Essential Care package for mental health and NTDs
- Volunteers
- 200 people
- Sponsor
- Liverpool School of Tropical Medicine
Lymphatic Filariasis, Onchocerciasis
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
Approximately 4,000 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas.
- Conditions
- Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections
- Trial name
- NCT02032043
- Testing
- Annual versus Semiannual Albendazole plus Ivermectin MDA
- Where
- Côte d’Ivoire
- Volunteers
- 14,457 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis, Epilepsy
Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
Onchocerciasis is a neglected tropical disease associated with epilepsy, particularly in areas of high Onchocerciasis volvulus transmission.
- Trial name
- OAETanzania (NCT05749653)
- Testing
- Bi-annual CDTI
- Where
- Tanzania
- Volunteers
- 6,500 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Loiasis
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the development of severe adverse reactions that are correlated with the number of circulating microfilariae in the blood.
- Trial name
- NCT01111305
- Testing
- Reslizumab, Diethylcarbamazine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Onchocerciasis (River Blindness), Schistosomiasis
Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations
Neglected Tropical Diseases (NTDs) are among the most common groups of diseases affecting over one billion people globally and are disproportionately concentrated in remote, underserved, and marginalized communities.
- Conditions
- Onchocerciasis (River Blindness), Schistosomiasis, Soil Transmitted Helminth (STH) Infections, Lymphatic Filariasis
- Trial name
- MISSION (NCT07707817)
- Testing
- Modified Mass Administration of Medicines Strategy, Albendazole 400 mg, Praziquantel 40 mg/kg
- Where
- Nigeria
- Volunteers
- 5,760 people, healthy volunteers welcome
- Sponsor
- Uwemedimo Friday Ekpo
Filariasis
Exhaled NO Testing in Filariasis
This study is looking at the difference in exhaled nitric oxide levels in patients with and without laboratory evidence of filariasis.
- Trial name
- NCT01628497
- Where
- Guyana
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
W. Bancrofti Filariasis
Research for Elim of Filariasis
Wuchereria bancrofti, is a mosquito-transmitted parasite that causes deforming lymphatic filariasis in the tropics. Improved treatment methods have led to new thinking that it should be possible to interrupt transmission and…
- Trial name
- NCT00145223
- Where
- Egypt
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphatic Filariasis
Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
The DOLF Triple Drug Therapy for Lymphatic Filariasis study will determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB…
- Trial name
- NCT02899936
- Testing
- 3 drug dose - IDA, 2 drug dose - DA
- Where
- 4 sites in Haiti, India and 2 more
- Volunteers
- 23,789 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Filarial; Infestation
Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection
Diethylcarbamazine (DEC) essentially a micro-filaricidal drug is given for 12 days as standard treatment for the clearance of W. bancrofti infection.
- Trial name
- NCT02005653
- Testing
- Diethylcarbamazine, Albendazole, Doxycycline
- Where
- India
- Volunteers
- 146 people
- Sponsor
- Indian Council of Medical Research
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited.
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer
- Trial name
- SkincAIr (NCT07506967)
- Testing
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Where
- 5 sites in Democratic Republic of the Congo, Ethiopia and 3 more
- Volunteers
- 2,420 people
- Sponsor
- Kenya Medical Research Institute